M
Meliora Therapeutics
Develops life-saving cancer therapies using cutting-edge science and machine learning
About Meliora Therapeutics
Meliora Therapeutics is a startup operating in the biotech industry, specifically in the field of oncology drug development. The company is focused on improving the success rate of cancer therapies, which currently stands at a mere 3%. Meliora aims to achieve this by accurately identifying the true mechanisms-of-action of chemical compounds used in cancer drugs. This approach is expected to lead to more effective and rapid drug development, thereby increasing the chances of successful treatments for patients.
Read full description
The company employs a range of advanced techniques, including genomics, computational methods, and machine learning, to enhance the drug development process. It operates a collaborative business model, with a team of biologists, chemists, bioinformaticians, data scientists, and engineers working together to create a drug discovery platform. This interdisciplinary approach is a key aspect of Meliora's strategy, as it believes that such collaborations are essential for taking therapeutics to the clinic.
Meliora's clients are primarily investors in the deep tech, biotech, oncology, and AI sectors. The company makes money by developing and licensing its drug discovery platform and the resulting therapies to these investors and potentially to pharmaceutical companies.
In summary, Meliora Therapeutics is a biotech startup that uses advanced techniques to improve the success rate of cancer therapies by accurately identifying the mechanisms-of-action of the drugs used in these therapies.
At a glance
- Status
- Operational
- Founded
- 2021
- Headquarters
- San Francisco, United States
- Employees
- 7
- Open positions
- None listed
- Dealroom signal
- 67.5/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Core AI, Spinout, Biotech and Pharma, AI Drug Discovery, Techbio, AI Applications, DT and LS
- Technology
- Artificial Intelligence
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Meliora Therapeutics.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SEED✓Equity / VC | Sep 2022 | $11M | $44M | Wes Sterman · ZhenFund · Village Global · BrightEdge | ↗ |
| SPINOUT✓Other financing | Jan 2021 | $0 | — | Cold Spring Harbor Biological Laboratory | — |
Growth signals
Latest recorded traffic for Meliora Therapeutics is 360 monthly website visits, up 500% over the last three months. Meliora Therapeutics's team declined 12.5% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed10 investors entered at this stage
ZhenFund
HOF Capital- WSWes Sterman
Village Global
BrightEdge
Obvious Ventures
Michael Polansky
Axial VC
Olive Capital
Pebblebed
Other known investors4 additional known investors
Cold Spring Harbor Biological Laboratory
Bayer Co.Lab
Hawktail
Outset
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Meliora Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Meliora Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.